The key elements of our strategy are to: Apply our expertise in multivalency primarily to validated targets to efficiently discover and develop superior medicines in large markets. Our drug discovery efforts are based on our expertise in multivalency. Multivalency involves the simultaneous attachment of a single molecule to multiple binding sites on one or more biological targets. We believe that by applying our expertise in multivalency we can discover medicines that will be superior to many market-leading medicines by substantially improving potency, duration of action and/or selectivity. Identify two structurally different product candidates in each therapeutic program whenever practicable. We believe that this can increase the likelihood of successfully bringing superior medicines to market. Partner with global pharmaceutical companies to accelerate development and commercialization of our product candidates. Our strategy is to seek collaborations with leading global pharmaceutical companies, such as GlaxoSmithKline and Astellas Pharma Inc., to accelerate development and commercialization of our product candidate pipeline at the strategically appropriate time. Leverage the extensive experience of our people. We have an experienced senior management team with many years of experience discovering, developing and commercializing new medicines with companies such as Bristol-Myers Squibb Company, Gilead Sciences, Inc., GlaxoSmithKline, Merck Co., Millennium Pharmaceuticals, Inc., and Pfizer Inc. Improve, expand and protect our technical capabilities. We have created a substantial body of know-how and trade secrets in the application of our multivalency approach to drug discovery. We expect to continue to make substantial investments in multivalency and other technologies to maintain what we believe are our competitive advantages in drug discovery.
Theravance, Inc. (Theravance) is a biopharmaceutical company with a pipeline of internally discovered product candidates. As of December 31, 2009, the Company is focused on the discovery, development and commercialization of small molecule medicines across a number of therapeutic areas, including respiratory disease, bacterial infections and gastrointestinal motility dysfunction. Its programs include VIBATIV (telavancin) with Astellas Pharma Inc. (Astellas) and its RELOVAI program (formerly referred to as Horizon) and the Bifunctional Muscarinic Antagonist-beta2 Agonist (MABA) program with GlaxoSmithKline plc (GSK).
The numerical value of theravance in Chaldean Numerology is: 1
The numerical value of theravance in Pythagorean Numerology is: 7
Images & Illustrations of theravance
Find a translation for the theravance definition in other languages:
Select another language: